Skip to main content
    B

    BioAge Labs, Inc (BIOA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $5.22
    -0.33 (-5.95%)

    Market Cap: $255.03M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    BioAge Labs, Inc (BIOA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    BioAge Labs reported revenue of $8.99M for the fiscal year ended Dec 31, 2025. That year, net income was -$80.61M with a net margin of -896.1%, operating cash flow was -$81.63M and free cash flow was -$82.35M. The quarter ended Sep 30, 2026 had revenue of $298.00K and net income of -$33.50M.

    Revenue and Margins

    Over the 12 years to Dec 2025, revenue grew from $2.67M, a compound annual rate of 10.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$8.99MN/A100.0%-1031.5%-896.1%
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2017$14.94M+80.6%-49.4%-736.2%-656.8%
    Dec 2016$8.27M+280.9%-65.2%-358.2%-271.7%
    Dec 2015$2.17M+40.8%-20.3%-1773.9%-1713.9%
    Dec 2014$1.54M-42.1%-291.7%-2281.5%-3008.5%
    Dec 2013$2.67MN/A-0.9%-1545.1%-1246.3%
    Annual, fiscal years ended Dec 2013 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013
    Revenue$8.99M$0$0$0$14.94M$8.27M$2.17M$1.54M$2.67M
    Cost of revenue$0$0$0N/A$22.32M$13.67M$2.61M$6.04M$2.69M
    Gross profit$8.99M$0$0N/A-$7.38M-$5.39M-$440.83K-$4.50M-$23.78K
    Research and development$73.97M$59.04M$33.89M$30.52M$5.47M$7.20M$20.29M$15.16M$16.58M
    Operating income-$92.78M-$78.19M-$48.40M-$39.97M-$110.01M-$29.63M-$38.53M-$35.20M-$41.18M
    Net income-$80.61M-$71.11M-$63.85M-$39.72M-$98.15M-$22.48M-$37.23M-$46.42M-$33.22M
    EBITDAN/A-$78.03MN/A-$39.35M-$88.72M-$13.29M-$33.07MN/A-$38.84M
    Fiscal years ended Dec 2013 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$298.00K$2.45M$2.77M$3.08M$2.05M$2.41M$1.45M$0$0$0$0$0
    Gross profit$298.00K$2.45M$2.77M$3.08M$2.05M$2.41M$1.45MN/A$0$0$0N/A
    Operating income-$37.41M-$29.33M-$25.38M-$28.42M-$23.14M-$24.77M-$16.45M-$25.36M-$24.75M-$15.27M-$12.81M-$13.60M
    Net income-$33.50M-$26.10M-$22.25M-$25.94M-$20.17M-$21.56M-$12.93M-$21.13M-$23.41M-$13.58M-$12.99M-$20.96M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $2.65M by $186.24M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013
    Total assets$294.89M$358.23M$25.92M$28.43M$69.51M$161.33M$143.09M$152.44M$114.08M
    Current assets$286.79M$357.10M$25.31M$28.03M$15.25M$31.42M$10.84M$57.09M$94.96M
    Cash and equivalents$188.89M$354.35M$21.64M$27.64M$4.63M$16.16M$6.97M$51.04M$83.73M
    Total liabilities$22.84M$35.11M$66.60M$140.99M$47.66M$112.84M$96.73M$94.91M$49.07M
    Short-term debt$2.65M$6.00M$26.67M$216.00K$4.92M$23.30M$10.30M$2.98M$6.52M
    Long-term debt$0$2.50M$8.20M$2.25MN/AN/AN/AN/AN/A
    Shareholder equity$272.05M$323.13M-$173.40M-$112.56M$21.85M$48.49M$46.36M$57.53M$65.01M
    Fiscal years ended Dec 2013 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$367.65M$396.93M$397.65M$294.89M$305.09M$322.15M$343.84M$358.23M$337.38M$164.40M$179.60M$25.92M
    Total liabilities$21.20M$22.02M$18.53M$22.84M$27.63M$27.37M$30.67M$35.11M$23.63M$361.53M$365.11M$199.32M
    Cash and equivalents$52.67M$73.96M$241.78M$188.89M$215.57M$220.33M$257.49M$354.35M$334.47M$159.09M$173.99M$21.64M
    Shareholder equity$346.45M$374.91M$379.12M$272.05M$277.46M$294.78M$313.17M$323.13M$313.75M-$197.13M-$185.51M-$173.40M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2017Dec 2016Dec 2015Dec 2014
    Operating cash flow-$81.63M-$51.52M-$37.36M-$36.18M-$29.79M-$37.62M-$32.20M-$22.45M
    Capital expenditures$719.00K$366.00K$166.00K$103.00K$0$0$0$0
    Free cash flow-$82.35M-$51.89M-$37.53M-$36.28M-$29.79M-$37.62M-$32.20M-$22.45M
    Share repurchases$0$542.00KN/AN/AN/AN/AN/AN/A
    Investing cash flow-$95.22M-$366.00K-$266.00K-$103.00KN/AN/AN/AN/A
    Financing cash flow$11.47M$381.20M$34.94M$2.50M$18.85M$47.22M$54.89M$78.65M
    Fiscal years ended Dec 2014 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$30.96M-$19.26M-$24.05M-$28.25M-$16.04M-$19.97M-$17.36M-$5.14M-$14.93M-$15.78M-$15.67M-$8.50M
    Capital expenditures$18.00K$328.00K$26.00K$112.00K$22.00K$159.00K$426.00K$26.00K$305.00K$35.00K$0$0
    Free cash flow-$30.98M-$19.59M-$24.07M-$28.36M-$16.07M-$20.13M-$17.79M-$5.16M-$15.24M-$15.82M-$15.67M-$8.50M
    Last 12 quarters

    Frequently Asked Questions About BIOA

    What is BioAge Labs' annual revenue?

    BioAge Labs reported revenue of $8.99M for the fiscal year ended Dec 31, 2025.

    Is BioAge Labs profitable?

    No. BioAge Labs reported net income of -$80.61M for the fiscal year ended Dec 31, 2025, with a net margin of -896.1%.

    How much free cash flow does BIOA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$81.63M minus capital expenditures of $719.00K produced free cash flow of -$82.35M.

    How much debt does BioAge Labs have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $2.65M and cash and equivalents of $188.89M.

    What is BIOA's profit margin?

    For the fiscal year ended Dec 31, 2025, BioAge Labs reported gross margin of 100.0%, operating margin of -1031.5% and net margin of -896.1%.